Hillary Clinton Challenges Big Pharma

The Democratic presidential candidate wants to cap out-of-pocket expenses on insurance plans.

Ryan Mcbride/ZUMA

Hillary Clinton rolled out her latest policy plank in Des Moines, Iowa, on Tuesday afternoon. The Democratic front-runner described how, if elected president next year, she would try to rein in the spiraling costs of prescription medications.

Clinton is spending this week of her campaign touring the country explaining her proposals for health care and touting the benefits of the Affordable Care Act. Obama’s success in passing health care reform poses a tricky problem for Clinton: championing health care expansion has long been one of her signature causes going back to Bill Clinton’s first term as president. But the current Democratic president has already passed the overall infrastructure for covering the uninsured across the country. Now Clinton will need to run on protecting that legacy, while tinkering with the ACA around the margins to bolster its weak points.

“As president I want to go further,” she said Tuesday. “I want to strengthen the Affordable Care Act.”

Her drug plan would start by capping the amount of out-of-pocket expenses consumers can be charged under insurance plans at $250 per month. Of course, transferring the extra costs onto the insurance companies wouldn’t solve the all of the problems, since insurers would likely make up for their expenses through higher premiums.

She said earlier this week that her goal is to implement policies that would reduce spending on prescription medications by $100 billion over the next 10 years and proposed a number of strategies reach that goal. For example:

  • Speeding up approval of generic drugs to clear any backlog.
  • Allowing consumers to buy their medications from countries where American pharma companies sell them at cheaper rates. (This would require the FDA to ensure that the drugs being sold in other countries are the same medications as the ones sold here.)
  • Grant Medicare the power to negotiate with drug companies on the prices they charge. This has long been a standard proposal pushed by Democrats who argue that the 40 million Medicare recipients would have a system-wide effect on the price of drugs.
  • Add requirements to drug companies who receive federal support, forcing them to redirect more of their profits back into R&D.

You can read a full explanation of her suggestions on Clinton’s website.

Pharma was already gunning for Clinton even before her speech announcing the policy proposal. As The Hill reported, the head of the pharmaceutical lobby preempted her statement with its own that blasted the plan, saying it “would turn back the clock on medical innovation and halt progress against the diseases that patients fear most.” Pharma might have good reason to be worried. On Monday, Bloomberg attributed a quick, steep drop in Nasdaq’s listing of biotech stocks to a Clinton tweet in which she linked to a New York Times article on a company that had jacked up the price of an old drug, saying, “Price gouging like this in the specialty drug market is outrageous.”


We recently wrapped up the crowdfunding campaign for our ambitious Mother Jones Corruption Project, and it was a smashing success. About 10,364 readers pitched in with donations averaging $45, and together they contributed about $467,374 toward our $500,000 goal.

That's amazing. We still have donations from letters we sent in the mail coming back to us, so we're on pace to hit—if not exceed—that goal. Thank you so much. We'll keep you posted here as the project ramps up, and you can join the hundreds of readers who have alerted us to corruption to dig into.

We Recommend


Sign up for our newsletters

Subscribe and we'll send Mother Jones straight to your inbox.

Get our award-winning magazine

Save big on a full year of investigations, ideas, and insights.


Support our journalism

Help Mother Jones' reporters dig deep with a tax-deductible donation.


Share your feedback: We’re planning to launch a new version of the comments section. Help us test it.